Immunic, Inc. (NasdaqCM: IMUX)
Health Care · Biotechnology · US
$7.95
-2.93% today · -11.1% 1Y
Immunic, Inc. (NasdaqCM: IMUX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $108.47M and employs 100 people.
Over the last twelve months the share price has lost 11.1%, trading between 5.06 and 17.43.
Tweenvest scores Immunic, Inc. across four factors: quality 35/100, value 33/100. Its strongest factor is quality.
IMUX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $108.47M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.00
- Dividend yield
- —
- Beta (5Y)
- 1.45
- 52-week high
- $17.43
- 52-week low
- $5.06
- Avg volume (3M)
- —
- Shares outstanding
- 13.64M
- Employees
- 100
- Next earnings
- —
About Immunic, Inc.
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
- ISIN
- US4525EP2001
- Founded
- 2016
- Listed since
- Apr 17, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| PDS Biotechnology CorporationNasdaqCM: PDSB | $110.16M | $1.52 | +10.14% |
| Conexeu Sciences Inc.NasdaqCM: CNXU | $109.72M | $3.77 | -3.08% |
| Great Novel Therapeutics Biotech & MedicalsTPEX: 7427 | $109.39M | NT$66.10 | -5.97% |
| Pharmosa Biopharm Inc.TPEX: 6875 | $109.08M | NT$27.00 | -9.70% |
| Humacyte, Inc.NasdaqGS: HUMA | $108.23M | $0.39 | -3.87% |
| Tenax Therapeutics, Inc.NasdaqCM: TENX | $107.12M | $1.83 | -2.14% |
| Maxigen Biotech Inc.TWSE: 1783 | $106.88M | NT$38.10 | +2.83% |
| Tevogen Inc.NasdaqGM: TVGN | $106.69M | $6.68 | -1.50% |
Figures last refreshed Oct 11, 2026.